ArticlePloS one2026

Pharmacokinetic model selection for infliximab based on inflammatory bowel disease phenotype and severity: Toward model-informed precision dosing.

Ana Homšek Ilić et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.